



31 August 2015

EXPIRY OF LISTED OPTIONS & WAIVER OF LISTING RULE 6.24

Actinogen Limited (Actinogen Medical, ASX: ACW), notifies the holders of the Company's 9,103,177 listed options (exercise price \$0.40, expiry date 30 September 2015) (ASX: ACWOA) (Listed Options) that the Listed Options will expire at 5.00 pm WST on 30 September 2015.

The Company advises that it has been granted a waiver by the ASX from Listing Rule 6.24 on the basis that the Listed Options are *'out of the money'* and the likelihood of holders exercising the Listed Options is remote. Accordingly, an option expiry notice will not be sent to the holders of the Listed Options unless the market price of the Company's shares exceeds \$0.30 before 30 September 2015.

The information required by item 6.1 of Appendix 6A of the Listing Rules is set out below:

- The number of Listed Options to which this notice applies is 9,103,177.
- On exercise each Listed Option entitles to holder receive one fully paid ordinary share in the Company. If all of the Listed Options were exercised, 9,103,177 fully paid ordinary shares in the Company would be issued.
- The exercise price of each Listed Option is \$0.40.
- The due date for payment of the exercise price is 5.00 pm WST on 30 September 2015.
- If payment is not received by the expiry date, the Listed Options will expire unexercised and all rights will cease.
- Official quotation of the Listed Options will cease on 23 September 2015, being five business days before the expiry date.
- The last available market price of the Company's shares was \$0.057 on 28 August 2015.
- The highest and lowest market price of the Company's shares during the three months immediately preceding the date of this letter were:
Highest: \$0.086 on 4 June 2015
Lowest: \$0.05 on 25 August 2015
- The exercise of the Listed Options is not underwritten.

ENDS

Actinogen Medical

Dr Bill Ketelbey

Managing Director

P: +61 2 9251 5620

E: bill.ketelbey@actinogen.com.au

About Actinogen Medical

Actinogen Medical is focused on the treatment of Alzheimer's disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results in mid-2015 and plans to undertake a Phase II study in 2016.